A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer

被引：0
|
作者：
Krop, I. E.
Beeram, M.
Modi, S.
Rabbee, N.
Girish, S.
Tibbitts, J.
Holden, S. N.
Lutzker, S. G.
Burris, H. A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Drug Dev, San Antonio, TX USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Genentech Inc, San Francisco, CA USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [2] A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Vukelja, S.
    Rugo, H.
    Vogel, C.
    Borson, R.
    Tan-Chiu, E.
    Birkner, M.
    Holden, S. N.
    Klencke, B.
    O'Shaughnessy, J.
    Burris, H. A.
    CANCER RESEARCH, 2009, 69 (02) : 71S - 71S
  • [3] A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+breast cancer (BC)
    Beeram, M.
    Burris, H. A., III
    Modi, S.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Krop, I. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [5] A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.
    Burris, H. A.
    Krop, I. E.
    Modi, S.
    Rodon, J.
    Lutzker, S. G.
    Holden, S. N.
    Bhattacharya, S.
    Sliwkowski, M. X.
    Beeram, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S104 - S104
  • [6] A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I.
    Modi, S.
    Tolcher, A.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S.
    Lutzker, S.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Trastuzumab-MCC-DM1 (TMAB-MCC-DM1), a first-in-class her2 antibody-drug conjugate (ADC) - A phase I study in patients (PTS) with Her2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I. E.
    Modi, S.
    Tolcher, A. W.
    Tibbitts, J.
    Rabbees, N.
    Girish, S.
    Lutzker, S. G.
    Holden, S. N.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 21
  • [8] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] A PHASE 2 STUDY OF THE HER2 ANTIBODY-DRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH TRASTUZUMAB, LAPATINIB, AND CHEMOTHERAPY
    Krop, I.
    LoRusso, P.
    Miller, K. D.
    Modi, S.
    Yardley, D.
    Rodriguez, G.
    Lu, M.
    Burington, B.
    Agresta, S.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 97 - 97
  • [10] Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer
    Myra F. Barginear
    Veena John
    Daniel R. Budman
    Molecular Medicine, 2012, 18 : 1473 - 1479
12345